Source comparison
Tesamorelin + Ipamorelin Blend: Protocol Comparison
| Protocol Type | Tesamorelin Dose | Ipamorelin Dose | Timing | Expected IGF-1 Elevation | Primary Outcome | Professional Assessment ||—|—|—|—|—|—|| Conservative (30s baseline) | 1mg nightly | 200mcg nightly | Pre-sleep | 15–25% from baseline | Visceral fat re
This comparison does not assign a generated winner or score.
- | Protocol Type | Tesamorelin Dose | Ipamorelin Dose | Timing | Expected IGF-1 Elevation | Primary Outcome | Professional Assessment ||—|—|—|—|—|—|| Conservative (30s baseline) | 1mg nightly | 200mcg nightly | Pre-sleep | 15–25% from baseline | Visceral fat reduction, metabolic optimisation | Appropriate for patients with baseline IGF-1 >180 ng/mL seeking preventive benefits without supraphysiological stimulation || Standard (30s active) | 1.5mg nightly | 250mcg nightly | Pre-sleep | 25–35% from baseline | Fat loss, lean mass preservation, lipid improvement | Most common protocol for healthy adults in early GH decline; balances efficacy and safety margin || Aggressive (late 30s/early 40s) | 2mg nightly | 300mcg nightly | Pre-sleep | 35–45% from baseline | Maximum visceral adipose reduction, recomposition | Reserved for patients with baseline IGF-1 <200 ng/mL or significant metabolic dysfunction; requires closer monitoring || Pulsed (5-day-on, 2-day-off) | 1.5mg on-days | 250mcg on-days